personal scheduler Hamburg 2013 - Main Site Press Release 2013 Call for Abstracts General Information Programme Overview Letter from the President Keynote Lectures Main Sessions NEW - Free Paper Session Instructional Courses World Retina Day Retinal Detachment Course Uveitis Course Other Symposia Surgical Skills Training Courses
hamburg banner

Treatment of Irvine-Gass syndrome with Ozurdex

Session Details

Session Title: Quick Fire Free Paper Session 04

Session Date/Time: Sunday 29/09/2013 | 11:00-13:00

Paper Time: 11:45

Venue: Hall C (Level 1)

First Author: H.Schilling GERMANY

Co Author(s):                  

Abstract Details

"Purpose:

To examine the outcome of treating cystoid macular oedema following cataract surgery with Ozurdex after failure of conventional therapy.

Setting:

The study was conducted at the Eye-Clinic of the St.-Johannes-Hospital Dortmund, Germany.

Methods:

Prospective interventional case series of 6 eyes of 6 patients who did not show any response after treatment with a daily dosage of 3 x 250 mg acetacolamide and topical non-steroidal antiinflammatory drugs for 4 weeks. The visul acuity was measured by ETDRS-charts at baseline and every 4 weeks after the injection of the implant. The central thickness of the retina was measured by SD-OCT at every visit which consisted in a full routine examination. Exclusion criteria were: previous operations on the the same eye, known steroid responder, known glaucoma and vitreomacular traction as detected in the SD-OCT. The implant containing 700 µg dexamethasone was injected as recommended by the manufacturer.

Results:

After a minimum follow-up of 2 months the visual acuity had increased in all patients with a mean of 23 letters. The central (foveal) thickness decreased by 307,8 µm in average. The intraocular pressure (IOP) raised from a mean of 13 mm Hg at baseline to a mean of 17,8 mm Hg. An elevation of IOP beyond 21 mm Hg occurred in only one patient which could succcessfully treated with topical antiglaucomateous medication.

Conclusions:

The intravitreal injection of Ozurdex represents a highly effective therapeutical option in cases of Irvine-Gass-Syndrome which are refractory to conventional therapy. According to our observations the effect is stable for at least 2 months after application. No financial interest."

Back to Freepaper Session
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy